Partnership Opportunities

To keep pace with an exciting new era in neuropsychiatry, with notable approvals on the horizon, biopharma must invest in novel solutions to de-risk the translational gap and advance its therapeutic candidates through the clinic.

The 6th Neuropsychiatric Drug Development Summit provides an unrivaled and timely opportunity to demonstrate your expertise to a highly engaged audience of leading psychiatric drug developers actively seeking new collaborations to support their preclinical and clinical development of more efficacious treatments to meet significant unmet needs in PTSD, depression, bipolar and many more. Maximize booming neuropsychiatric progress and pipeline expansion this year and ensure your solution is in the spotlight.

Current Partners:

Neuropsychiatric Drug Developers Need Your Help With:

Optimized biomarker platforms to obtain more objective, reliable measurements of drug-induced effects on synaptic plasticity and behavioral symptoms

Digital monitoring platforms that can be harnessed to demonstrate clinically meaningful results of changes in mood across psychiatric patient populations

Translatable in vivo models for studying effects of psychotropic drug candidates on mood and behavior

More robust in vitro recapitulation of psychiatric disorders using iPSC-derived neurons and organoids

Support with clinical study design to mitigate placebo effect and
Manage practical burdens associated with psychedelic trials

Why Partner?

  • Present to an extensive audience of high seniority decision makers from leading neuropsychiatry biopharma in one highly focused forum
  • Position yourself as the go-to commercial partner for CNS drug developers heavily investing in novel innovations to drive future therapeutic research to meet significant unmet needs in mental health disorders
  • From established biopharma to emerging start-ups, network one-to-one with stakeholders to understand their specific requirements first-hand